Development of an Alternative Monoclonal Antibody Polishing Step - The authors describe a mAb polishing step using salt tolerant interaction membrane chromatography. - BioPharm International


Development of an Alternative Monoclonal Antibody Polishing Step
The authors describe a mAb polishing step using salt tolerant interaction membrane chromatography.

BioPharm International
Volume 25, Issue 5, pp. 34-46

Analytical techniques

Antibody concentrations in purified solutions were determined by the absorbance at 280 nm, using the NanoDrop spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). Size exclusion high performance liquid chromatography (SE–HPLC) was used to monitor the size heterogeneity of mAbs under native conditions on Agilent HPLC system using ChemStation as the controlling software (Santa Clara, CA). A TSK-Gel G3000SWXL column (Tosoh Bioscience, Montgomeryville, PA) was utilized to separate HMW species, monomers, and fragments. The mobile phase was phosphate buffer saline (without Ca2+ and Mg2+ ), pH 7.2 (Life Technologies, Carlsbad, CA).

A CHO host cell protein (CHOP) kit (Cygnus Technologies, Southport, NC) was used to determine the residual HCP level in purification in-process samples and purified mAb product during the screening stage of experiments according to the manufacturer's protocol. The HCP level in antibodies purified on STIC Nano was also measured by electrochemiluminescence (ECL) technology (Meso Scale Discovery or MSD, Gaithersburg, MD) developed at ImClone. Briefly, 25 L of 3 g/mL in-house purified anti-CHOP capturing antibodies were immobilized overnight on a 96-well MSD plate. The plate was blocked for 1 h with 3% BSA at room temperature. 25 L of mAbs in 2-fold serial dilutions and HCP standards were added into the plate and incubated for 2 h at room temperature. The bound HCPs were detected by addition of 25 L of biotinylated anti-CHOP probe at 3 g/mL, which was then detected by the addition of 25 L of streptavidin conjugated sulfo-Tag at 3 g/mL. After the completion of reaction, 150 L of MSD buffer was added and the plate was read with MSD SECTOR Imager 2400 for relative electrochemiluminescence units (ECLU). The intensity of the ECLU was proportional to the amount of residual HCP present in antibodies by extrapolation from the standard curve with a quantification limit of 16 ng/mL. All HCP results were normalized to the in-house CHOP standards.

The leached MabSelect SuRe ligand in antibodies was determined using the RepliGen's protein A ELISA kit (Waltham, MA) with a detection limit of 0.1 ng/mL according to the manufacturer's protocol. Residual CHO DNA in antibodies was measured by quantitative PCR (qPCR) using the resDNASEQ quantitative CHO Kit (Life Technologies, Carlsbad, CA), combining high-recovery PrepSEQ sample preparation and TaqMan based-quantitation. The assay was developed at ImClone using in-house CHO DNA standards. The quantification limit of the assay was 0.1 pg/mL.


Condition screening and optimization using 96-well plates

Table I
Using protein A column chromatography under our platform operating conditions, we first prepared four antibodies, which served as model proteins to evaluate STIC as an alternative antibody polishing platform to AEX chromatography. These partially purified proteins and their properties are shown in Table I. Among them, Mab-D and Mab-S showed poor solubility at low ionic strength solution conditions (< 5 mS/cm), which posed challenges to our current purification platform process. Mab-T was considered as the worst-case scenario material in terms of levels of residual HCP and HMW impurities. Thus it was used here to illustrate the procedure of condition screening and optimization. Process yield, HCP, and HMW were evaluated during the condition screening and optimization. Although the study described here focused on HCP and HMW, a similar method could be applied for other impurities.

Figure 1
The STIC equilibration buffer conditions were first screened using a Sartorius Sartobind STIC 96-well plate in a full factorial experimental design, as described in the Materials and Methods section. The load eluate (or flowthrough) and wash from each well, representing the purified product from an experimental run, were collected and evaluated for yield, HCP, and HMW. More than 90% process yield was achieved in all 30 experimental runs. The residual HCP and HMW levels in the STIC purified Mab-T were summarized in Figure 1. The residual HCP was <50 ppm at all tested conditions. Higher HCP removal was achieved when the operating conditions moved to the center of pH-NaCl contour plot (see Figure 1a). In most cases, for a given NaCl concentration, with increasing pH, HCP removal efficiency increased to the highest point and then started to decrease. This finding suggests that the optimal pH operating window for Mab-T is at pH 7.0–7.5.

The presence of an optimal operating pH window is consistent with the amine protonation hypothesis reported previously (21, 23). As pH increases from 6.5 to 8.5, amine groups are less protonated. Thus, positive charges on the ligands available to bind impurities decrease (21). Meanwhile, with increasing pH, there is an increase in the net negative charge of host cell proteins, which results in more efficient binding to the positively charged ligands on the membrane adsorber. The presence of an optimal pH operating window is due to the combination of amine protonation on the STIC membrane adsorber and changes in protein surface charges.

In addition, in the pH range of 6.5–8.0, HCP removal was not dramatically affected by NaCl concentration, supporting the salt tolerant nature of the STIC membrane adsorber. Through this quick, full factorial DOE study using 96-well plates, optimal buffer conditions for HCP removal were identified.

Figure 2
We next examined the impact of equilibration buffer conditions on the removal of HMW from the partially purified Mab-T. With the understanding that in most cases, HMW level can be controlled to below 2.0% through pre-polishing steps, the goal of HMW removal in this study was to reduce HMW species from 5.0% in the load to 3.0% in the flowthrough. When operating pH was increased from 6.5 to 8.5, the HMW in the purified Mab-T increased from 2.7% to 4.0% as shown in Figure 1b. A concomitant decrease in the IgG monomer was observed, suggesting that the HMW removal was less efficient as the pH increased. By contrast, HMW removal was not sensitive to NaCl concentration, particularly in the range of 20–120 mM NaCl. These findings further suggest that the process performance of Sartobind STIC is a result of its salt tolerant nature, supporting a wide design space of solution ionic strength or NaCl concentration. In order to reduce the HMW in the final product to 3.0% and HCP to less than 30 ppm, pH 7.0–7.5 and 25–75 mM NaCl were selected for further condition optimization.

Figure 3a
The initial buffer conditions developed in the screening experiments were further optimized through 12 additional experimental runs on a STIC 96-well plate via a central composite design (pH: 7.0–7.5, and NaCl concentration: 25–75 mM). The STIC response surfaces of process yield, residual HCP, and HMW level, were defined based on these runs. Again, each well in a STIC 96-well plate represented one unique combination of experimental conditions. As expected, >94% process yield was achieved in all experimental runs. The sweet spot of the equilibration buffer conditions is illustrated as a pH-NaCl contour plot (see Figure 2). When STIC was operated in the window of pH 7.2–7.3, and 30–60 mM NaCl, HCP was reduced to a lower level (< 20 ppm) and HMW to 3.0%.

blog comments powered by Disqus



Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Novartis Sells Influenza Vaccine Business to CSL for $275 Million
October 27, 2014
Author Guidelines
Source: BioPharm International,
Click here